Glucocerebrosidase (GBA1) (GBA1)

Glucocerebrosidase (GBA1) is a lysosomal enzyme essential for the hydrolysis of glucosylceramide into glucose and ceramide, a key step in the degradation of complex sphingolipids [1][2]. It functions within the lysosomal pathway, where its activity is supported by the activator protein saposin C and a specific lipid environment [3]. Mutations in the GBA1 gene lead to a significant reduction in enzyme activity, causing the accumulation of glucosylceramide in the lysosomes of macrophages, which results in the clinical manifestations of Gaucher disease, such as hepatosplenomegaly and cytopenia [4][5]. Beyond its role in rare metabolic disorders, GBA1 is a major genetic risk factor for Parkinson's disease and related synucleinopathies, as its dysfunction impairs the clearance of alpha-synuclein through the autophagy-lysosome pathway [6][7]. Therapeutic strategies targeting this molecule include enzyme replacement therapies (ERT) to provide functional protein and pharmacological chaperones designed to stabilize misfolded variants and enhance their trafficking to the lysosome [8].

Other names

Acid beta-glucosidaseGlucosylceramidaseGBAD-glucosyl-N-acylsphingosine glucohydrolaseGlucosylceramide beta-glucosidaseAcid beta-glucosidase 1

Enzyme replacement therapy (ERT) involves the administration of recombinant glucocerebrosidase to supplement deficient endogenous levels; pharmacological chaperones bind to the enzyme to stabilize its conformation, preventing premature degradation and promoting trafficking to the lysosome.